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Images of brain function, popularly called “neuroimages,” have become a mainstay of
contemporary communication about neuroscience and mental health. Paralleling media
coverage of neuroimaging research and the high visibility of clinics selling scans is
pressure from sponsors to move basic research about brain function along the translational
pathway. Indeed, neuroimaging may offer benefits to mental health care: early or tailored
intervention, opportunities for education and planning, and access to resources afforded
by objectification of disorder. However, risks of premature technology transfer, such as
misinterpretation, misrepresentation, and increased stigmatization, could compromise
patient care. The insights of stakeholder groups about neuroimaging for mental health care
are a largely untapped resource of information and guidance for translational efforts. We
argue that the insights of key stakeholders—including researchers, healthcare providers,
patients, and families—have an essential role to play upstream in professional, critical, and
ethical discourse surrounding neuroimaging in mental health. Here we integrate previously
orthogonal lines of inquiry involving stakeholder research to describe the translational
landscape as well as challenges on its horizon.
Keywords: neuroethics, bioethics, qualitative research, neuroimaging, psychiatry
INTRODUCTION
Images of brain function have become a mainstay of contem-
porary communication about neuroscience and mental health.
Paralleling media coverage of neuroimaging research and the pro-
liferation of highly publicized clinics in the United States, Canada,
and Japan that sell brain scans for mental health assessments,
is pressure from sponsors to move basic research about brain
function along the translational pathway. Indeed, neuroimaging
may offer potential benefits to mental health care: early or tai-
lored intervention, opportunities for education and planning,
and access to resources afforded by image representation of dis-
ease processes. However, premature or inappropriate technology
transfer poses many potential risks, such as misrepresentation or
misunderstanding of results that can compromise patient care.
Some scientists and ethicists also caution against risks of increased
social distance, stigma, and marginalization. To date, discussion
about translational efforts largely misses a prime opportunity to
inform professional debates, risk-benefit assessments, and policy
developments with direct knowledge of how end-user stakehold-
ers could be affected. Here, we synthesize known perspectives
about research on clinical neuroimaging in mental health care,
and advance an imperative to shift stakeholder inquiry from back
stage murmurs to front stage voices. We note that our discussion
focuses on functional neuroimaging modalities, and we use the
term neuroimage to refer to images of brain function.
PERSPECTIVES ON A “BRAIN FRAME” FOR MENTAL HEALTH
Brain disease models of mental health and illness dominate cur-
rent Western psychiatric theory and practice, displacing earlier
notions of psychopathology as disorders of psyche, “maladies of
the soul,” or moral shortcomings. Support for this shift toward a
neuroscientific epistemology has been demonstrated by initiatives
in the United States such as the 1990 launch of the Decade of
the Brain by the Library of Congress and National Institute of
Mental Health (NIMH), a multi-institutional effort to promote
brain research (Project on the Decade of the Brain, 2000), and
the codification of a goal to “accelerate the pace of new discoveries
by fostering research that translates findings from basic science into
new treatments addressing fundamental mechanisms that cut across
current diagnostic categories” by the Research Domain Criteria
(RDoC) program of the NIMH (Insel et al., 2010). Prominent
psychiatrists have endorsed a brain disease model of mental ill-
ness as a reconceptualization necessary to “transform the practice
of psychiatry” with the legitimizing force of neuroscience (Insel
and Wang, 2010).
Given the prevailing brain disease model, it is not surprising
that mental health research has embraced neuroimaging tech-
nologies such as positron emission tomography (PET), single
photon emission computed tomography (SPECT) and, most
recently, functional magnetic resonance imaging (fMRI) as
instrumental to the identification of neural processes underlying
mental health diagnoses (Agarwal et al., 2010). The hope is
that neuroimaging research will contribute to evidence-based
practice, and lead to refined diagnostics and targeted treatment
directed by neurobiology (Lennox, 2009; Linden and Fallgatter,
2009; Insel and Wang, 2010). Indeed, the promises of an antic-
ipated translation of neuroimaging—potentially combined with
genetic testing (Linden and Thome, 2011)—to mainstream
psychiatric clinical care in the future are significant. Already
some private clinics have capitalized on the therapeutic promise
of neuroimaging by offering brain scans as part of mental health
evaluation—a service whose high demand is evidenced by rapid
expansion and lengthy wait lists (Cyranoski, 2011; Amen Clinics
Home Page, 2012). This industry thrives despite a dearth of
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support for routine clinical use of neuroimaging by the broader
psychiatric community (American Psychiatric Association, 2005;
Adinoff and Devous, 2010a,b).
Despite the breadth of neuroimaging research on mental
health disorders, missing from discussions about the anticipated
integration of neuroimaging in routine mental health care are the
voices of stakeholders. While everyone in society may be affected
to varying degrees by the outcome of medical technologies, here
we use the term stakeholder more narrowly to refer to individu-
als who have a vested interest in current and future applications
of neuroimaging in mental health care or who are the intended
users or beneficiaries of the technology. Stakeholders may include
neuroimaging and mental health researchers, providers at all lev-
els of care, individuals living with mental health disorders as well
as their employers, caregivers, and loved ones. If neuroimaging
technology might promote both physical and mental well-being
as proponents suggest, should not stakeholder priorities, experi-
ences, concerns, and expectations be known and integrated into
translational efforts? We think the answer is yes. As neuroimag-
ing technology advances along its projected trajectory toward
the clinic and scholars engage in ethics recommendations and
policy development, stakeholder perspectives have an essential
role to play in informing the ethical advancement of neurotech-
nologies and patient care. In 2010, anthropologist and ethnogra-
pher on issues in mental health Emily Martin suggested and we
agree that:
We are far from a full understanding of why brain-based under-
standings are taken up enthusiastically in some institutions and
not in others, and by some scholars and not others . . . The schol-
arly debates over what critical position to take in relation to
neurological accounts of human social life would benefit from
looking into what is at stake among non-experts struggling over
how to position the brain in their lives (Martin, 2010).
STAKEHOLDER VOICES ON NEUROIMAGING
Different approaches have been used to date to explore how
neuroimaging may affect mental health care now and in the
future. For example, Joseph Dumit and Simon Cohn have used
ethnographic approaches to explore the ways in which images
of brain function influence researcher, patient, and popular
understandings of mental illness and intervention (Dumit, 1999,
2003, 2004; Cohn, 2010). Dumit’s 2004 ethnography Picturing
Personhood pioneered inquiry into stakeholder perspectives on
neuroimaging, integrating interviews with PET researchers, semi-
otic analyses, observation, and theoretical reflection into a coher-
ent narrative about the emergence and influence of neuroimages.
Although Dumit’s work focused exclusively on PET scanning,
it set the scientific, clinical, legal, and societal context for neu-
roimaging and provided a backdrop for future empirical work.
Dumit, as well as Cohn, probed the ways in which neuroimages
create new insights into and beliefs about the brain, personal
identity, and lived experience. This line of inquiry has developed
into the growing body of “critical neuroscience” literature, a dis-
course that examines how neuroscience generates new knowledge
and the ways in which that knowledge is interpreted and incorpo-
rated into social and political interactions (Choudhury and Slaby,
2012).
Our own group has used an anticipatory ethics approach—
the study of ethics and probable social issues associated with
emerging technologies prior to mainstream use—with survey and
interview methods to probe complementary questions about the
potential of neuroimaging to impact patient, health care provider,
and parent groups as well as the lived experience of mental health
care (Illes et al., 2008; Borgelt et al., 2011, 2012a,b; Anderson and
Illes, 2012; Buchman et al., 2012; Eijkholt et al., 2012; Anderson
et al., under review). In one survey study, adults living with major
depressive disorder and psychiatrists reported high receptivity to
the use of neuroimaging for treatment planning (Illes et al., 2008).
Their hope was that brain scans would help patients to under-
stand and cope with the mental illness and mitigate the effects
of stigma and self-blame. The data suggested that neuroimag-
ing could play a significant role in alleviating the social burden
attached to a diagnosis of mental illness. Later studies using quali-
tative methods enrich this initial work with evidence about beliefs
about and hopes for what the technology would provide for diag-
nosis and treatment tailoring of mental health disorders, again
across stakeholder groups of researchers (Cohn, 2010), providers
(Borgelt et al., 2011, 2012a,b), adults with mood, psychotic, and
obsessive compulsive disorders (Cohn, 2010; Buchman et al.,
2012), and parents of children with ADHD (Borgelt et al., 2012b).
Key to the appeal for patients, parents, and even some
providers is the apparent objectivity of neuroimages. Perceptions
of objectivity create a new frame through which patients and
parents construct an understanding of mental illness as brain
disorder, with black-and-white evidence of neurobiological dys-
function replacing subjective feelings of “being crazy” (Dumit,
2003; Cohn, 2010; Buchman et al., 2012). Interviews of adults
with mood disorder suggest that the visual reaffirmation offered
by neuroimages legitimizes the experience of mental illness with
authoritative representation of the phenomenon (Dumit, 2003;
Cohn, 2010; Buchman et al., 2012). This representation leads
many patients to adopt a dualist distinction between me and my
brain, orme andmy illness. Indeed, patients and parents hope that
the stigmas somessily entangled inmental illness—dynamic webs
of biology, psychology, spirituality, and sociality—will slip away
from the glossy neuroimage. Patients wish to mitigate social dis-
tance and fear (Buchman et al., 2012), while parents strive to dis-
pel what they perceive to be a common practice of parent-blame
(Borgelt et al., 2012b).
In addition to reducing stigma and improving understand-
ing of their child, parents also hang their high receptivity to
neuroimaging on a desire for objective diagnostics to ameliorate
doubts about medication and to aid their efforts to champion
resources for their children (Borgelt et al., 2012b). For parents,
technology is purely instrumental and its appeal may reduce to
a simple, enduring hope for “anything that would help” (Borgelt
et al., 2012b).
Adult patients and parents of children with ADHD voice few
or no explicit concerns about the potential risks of neuroimag-
ing (Cohn, 2010; Borgelt et al., 2012b; Buchman et al., 2012).
However, they do underscore the vulnerability that corresponds
to high hopes and expectations and thereby point to areas in
which clinical and ethical challenges will likely arise. Inextricable
from high hope is the potential for great disappointment.
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For example, while these stakeholders desire decreased social
stigmatization, prior survey work reports that uptake of biological
explanations for mental illness by the general public does not nec-
essarily correlate to increased tolerance and may even reinforce
certain stigmatizing practices such as social distancing (Phelan,
2005; Pescosolido et al., 2010; Angermeyer et al., 2011). Although
the persuasive power of neuroimages may be positively applied
to endeavors such as promoting patient and public education
and informing treatment decision-making, caution and atten-
tion from the academic and medical communities are needed
to mitigate patient manipulation or exploitation, inappropriate
application for clinical diagnosis, and coercive uses for treatment
compliance. Not surprisingly, providers are more cautious. They
do describe downstream clinical benefits of correlating men-
tal illness to neurobiological mechanisms, such as refining the
categorization of disorders, improving diagnostic criteria, and
enabling prediction of treatment response. Balancing their dis-
cussion of benefit, however, providers focus more significantly on
the potential for compromised patient care, diminished value of
the comprehensive assessment, and disruptions in doctor-patient
communication (Illes et al., 2008). Their anticipation of the
risks of predictive applications of neuroimaging are particularly
salient.
Together with researchers, providers also diverge from patients
and parents on the point that neuroimaging promises an objective
representation of subjective experience with a “picture of a broken
brain” (Buchman et al., 2012). They view neuroimaging as a sta-
tistically derived tool rather than a signifier of objective truth. As
a by-product, researchers, and providers couch their discussion of
potential risks and benefits associated with clinical neuroimaging
in mental health care and are more cognizant (or at least more
expressive) of the current limitations of the technology (Cohn,
2010; Borgelt et al., 2011).
Given the differences in perspectives among stakeholder
groups regarding beliefs about the nature of neuroimaging and
recognition of its limitations and risks, a key determinant of
stakeholders’ views is their relationship to the technology—that
is, whether they are a recipient (patient or parent) or a pre-
scriber (researcher or provider) of the technology (Figure 1).
The impact of one’s relationship to technology overarches other
possible determinants such as diagnostic category or decision-
making role. Though intuitive to some extent, identifying poten-
tial mediators of stakeholder perceptions and such as this can
only be supported once stakeholder perspectives are solicited and
compared.
MOVING FORWARD: NOWWHAT?
High receptivity to neuroimaging emerges across studies of stake-
holder groups—among neuroimaging researchers and mental
health care providers who see it as a valuable tool for unlock-
ing the mechanisms of mental illness and improving patient care,
and among adult patient and parent groups who hope that neu-
roimaging will help transform their lived experience. These are
well-articulated messages despite differences in study design, in
the milieu in which they were elucidated, in the nuances of
qualitative analysis, and even with respect to the neuroimaging
modality and format to which they refer (Beaulieu, 2002; Keehner
et al., 2011). However, high receptivity to neuroimaging among
these stakeholders does not alone justify a normative conclusion
to usher neuroimaging faster along the translational pathway.
Indeed, this pertains to how the academic, medical, and
policy communities should act on these data—a question that
has been central in debates among academics seeking to inte-
grate normative and empirical approaches to ethical and policy
challenges (Borry et al., 2005; Goldenberg, 2005; Arras, 2007;
Draper and Ives, 2007; Kon, 2009; Braddock and Magnus, 2010).
Purely normative approaches to ethics and policy development
may be weakened by unfounded assumptions and a disconnect
between armchair rationale and the realities of context and cul-
ture. However, critics of empirical approaches caution against
simple poll-taking or consensus-building because they see it nar-
rowly describing what is rather than synthesizing what ought to
be. Such criticisms might impugn a review of stakeholder per-
spectives, arguing that such data exacerbate the is-ought problem
and lack normative directivity. Empirical work in anticipatory
ethics—such as on future applications of neuroimaging in mental
health care—is even a step removed from describing what is in its
attempt to forecast the elusive will be.
We, like others (Borry et al., 2005; Draper and Ives, 2007),
however, envision an evidence-based ethics that is attentive to
the complex social, phenomenological, moral, and technologi-
cal dimensions of issues in biomedicine, that is equally reflec-
tive about its limitations and is critically normative. While we
acknowledge that the hypothetical nature of anticipatory research
on stakeholder views poses inherent limitations on its con-
clusions, hypotheticals conversely serve as perhaps its greatest
strength. Engaging the complexity of stakeholder views proac-
tively, before neuroimaging is ushered further toward the doors
of the mainstream mental health clinic, allows for upstream
incorporation of the views they express as well as the upfront
management of concerns or hype. And, to whom should policy-
makers listen when perspectives diverge? To this question, the
pragmatic answer is: all of them. The practical reality is that
divergences of perspective across groups suggest probable ten-
sions that, if left unaddressed, will inevitably play out in the clinic.
Moving forward with empirical inquiry, normative analysis, and
policy development—the “now what” question—we encourage
continued efforts to collect stakeholder perspectives, integrate
them upstream of clinical translation, and proactively address
ethical and practical challenges borne out by differences in stake-
holders’ hopes, concerns, and changing conceptions of mental
health.
CONCLUSION
Past and contemporary research has reinforced the importance
of the voice of stakeholders in the translational pathway for neu-
roimaging, and revealed how images of brain function will be
received, perceived, and incorporated into the experience men-
tal health care. Neuroimaging is expected to have a profound,
expansive impact on the conceptualization of mental illness and
provision of mental health care. The magnitude and nature of
the effects of neuroimaging on its end-users and social context
must continue to be elucidated to inform policy and practice in
the future.
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FIGURE 1 | Translational relationships to brain scan technology.
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